MicroRNA profiling in cancer

Clinical Science

Volumn 121, Issue 4, 2011, Pages 141-158

  Munker, Reinhold ^a,b   Calin, George A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer; Gene expression profile; Leukaemia; Malignancy; Microrna; Non coding RNA

Indexed keywords

MICRORNA; MICRORNA 10A; MICRORNA 125A 5P; MICRORNA 125B; MICRORNA 128; MICRORNA 135A; MICRORNA 145; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 17 3P; MICRORNA 17 92; MICRORNA 191; MICRORNA 19A; MICRORNA 19B; MICRORNA 203; MICRORNA 205; MICRORNA 206; MICRORNA 21; MICRORNA 212; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 25; MICRORNA 29; MICRORNA 342; MICRORNA 34A; MICRORNA 34C 5P; MICRORNA 99B; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENE THERAPY; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DNA MICROARRAY; GENE OVEREXPRESSION; GENETIC PROCEDURES; GENETIC RISK; GLIOBLASTOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MESOTHELIOMA; MICRORNA PROFILING; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RNA SYNTHESIS; SEZARY SYNDROME; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE;

FEMALE; GENE EXPRESSION PROFILING; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICRORNAS; NEOPLASMS; RISK ASSESSMENT; RNA, NEOPLASM;

EID: 79956190689     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110005     Document Type: Review

References (124)

1. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M. and Croce, C. M. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101, 2999-3004.
2. Krol, J., Loedige, I. and Filipowicz, W. (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597-610.
3. Sakurai, K., Furukawa, C., Haraguchi, T., Inada, K.-I., Shiogama, K., Tagawa, T., Fujita, S., Ueno, Y., Ogata, A., Ito, M. et al. (2011) MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res. 71, 1-10.
4. Fan, X., Shi, L., Fang, H., Cheng, Y., Perkins, R. and Tong, W. (2010) DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin. Cancer Res. 16, 629-636.
5. Liu, C. G., Spizzo, R., Calin, G. A. and Croce, C. M. (2008) Expression profiling of microRNA using oligo DNA arrays. Methods 44, 22-30.
6. Sato, F., Tsuchiya, S., Terasawa, K. and Tsujimoto, G. (2009) Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS ONE 4, e5540.
7. Yauk, C. L., Rowan-Carroll, A., Stead, J. D. H. and Williams, A (2010) Cross-platform analysis of global microRNA expression technologies. BMC Genomics 11, 330.
8. Ferdin, J., Kunej, T. and Calin, G. A. (2010) Non-coding RNAs: identification of cancer-associated microRNAs by gene profilingTechnol. Cancer Res. Treat. 9, 1-16.
9. Calin, G. A. and Croce, C. M. (2007) Investigation of microRNA alterations in leukemias and lymphomas. Methods Enzymol. 427, 193-213.
10. Schweiger, M. R., Kerick, M., Timmermann, B. and Isau, M. (2011) The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev., doi: 10.1007/s10555-011-9278-z.
11. Codony, C., Crespo, M., Abrisqueta, P., Montserrat, E. and Bosch, F. (2009) Gene expression profiling in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. 22, 211-222.
12. Calin, G. A., Dumitru, C., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Alder, H., Rattan, S., Keating, M., Rai, K. et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529.
13. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M. et al. (2005) MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801.
14. Calin, G. A. and Croce, C. M. (2009) Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 114, 4761-4770.
15. Visone, R., Rassenti, L. Z., Veronese, A., Taccioli, C., Costinean, S., Aguda, B. D., Volinia, S., Ferracin, M., Palatni, J., Balatti, V. et al. (2009) Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 114, 3872-3879.
16. Rossi, S., Shimizu, M., Barbarotto, E., Nicoloso, M. S., Dimitri, F., Sampath, D., Fabbri, M., Lerner, S., Barron, L. L., Rassenti, L. Z. et al. (2010) MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116, 945-952.
17. Küppers, R. (2009) The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 9, 15-27.
18. Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E. and Monzo, M. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114, 2945-2951.
19. Van Vlierberghe, P., DeWeer, A., Mestdagh, P., Feys, T., De Preter, K., De Paepe, P., Lambein, K., Vandesompele, J., Van Roy, N., Verhasselt, B. et al. (2009) Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+B-cells reveals a distinct subset of differentially expressed miRNAs. Br. J. Haematol. 147, 686-690.
20. Calvo, K. R., Traverse-Glehen, A., Pittaluga, S. and Jaffe, E. S. (2004) Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma. Adv. Anat. Pathol. 11, 227-238.
21. Iqbal, J., Liu, Z. F., Deffenbacher, K. and Chan, W. C. (2009) Gene expression profiling in lymphoma diagnosis and management. Best Pract. Res. Clin. Haematol. 22, 191-210.
22. Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W. et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 13520-13525.
23. Zhao, J. J., Lin, J., Lwin, T., Yang, H., Guo, J., Kong, W., Dessureault, S., Moscinski, L. C., Rezania, D., Dalton, W. S. et al. (2010) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115, 2630-2639.
24. Ballabio, E., Mitchell, T., van Kester, M. S., Taylor, S., Dunlop, H. M., Chi, J., Tosi, I., Vermeer, M. H., Tramonti, D., Saunders, N. J. et al. (2010) MicroRNA expression in Sézary syndrome: identification, function and diagnostic potential. Blood 116, 1105-1113.
25. Yamanaka, Y., Tagawa, H., Takahashi, N., Watanabe, A., Guo, Y. M., Iwamoto, K., Yamashita, J., Saitoh, H., Kameoka, Y., Shimizu, N. et al. (2009) Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 114, 265-3275.
26. Roccaro, A. M., Sacco, A., Chen, C., Runnels, J., Leleu, X., Azab, F., Azab,A.K., Jia,X., Ngo, H. T.,Melhem, M. R. et al. (2009) MicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 113, 4391-4402.
27. Bacher, U., Kohlmann, A., Haferlach, C. and Haferlach, T. (2009) Gene expression profiling in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol. 22, 169-180.
28. Garzon, R., Volinia, S., Liu, C. G., Fernandez-Cymering, C., Palumbo, T., Pichiorri, F., Fabbri, M., Coombes, K., Alder, H., Nakamura, T. et al. (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183-3189.
29. Garzon, R., Heaphy, C. E. A., Havelange, V., Fabbri, M., Volinia, S., Tsao, T., Zanesi, N., Kornblau, S. M., Marcucci, G., Calin, G. A. et al. (2009) MicroRNA29b functions in acute myeloid leukemia. Blood 114, 5331-5341.
30. Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L. et al. (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl. Acad. Sci. U.S.A. 107, 7473-7478.
31. Mi, S., Li, Z., Chen, P., He, C., Cao, D., Elkahloun, A., Lu, J., Pelloso, L. A., Wunderlich, M., Huang, H. et al. (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc. Natl. Acad. Sci. U.S.A. 107, 3710-3715.
32. Yong, A. S. M. and Melo, J. V. (2009) The impact of gene profiling in chronic myeloid leukemia. Best Pract. Res. Clin. Haematol. 22, 181-190.
33. + cells. Blood 109, 4399-4405.
34. Bueno, M. J., Pérez de Castro, I., Gómez de Cedr ón, M., Santos, J., Santos, J., Calin, G. A., Cigudosa, J. C., Croce, C. M., Ferńandez-Piqueras, J. and Malumbres, M. (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13, 496-506.
35. +cells increases USF2-mediated cell growth. Mol. Cancer Res. 6, 1830-1840.
36. San José-Enériz, E., Román-Góomez, J., Jiménez-Velasco, A., Garate, L., Martin, V., Cordeu, L., Vilas-Zornoza, A., Rodríguez-Otero, P., Calasanz, M. J., Prósper, F. and Agirre, X. (2009) MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 8, 69.
37. Mullighan, C. G. and Downing, J. R. (2009) Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 23, 1209-1218.
38. Mi, S., Lu, J., Sun, M., Li, Z., Zhang, H., Neilly, M. B., Wang, Y., Qian, Z., Jin, J., Zhang, Y. et al. (2007) MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 104, 19971-19976.
39. Fulci, V., Colombo, T., Chiaretta, S., Messina, M., Citarella, F., Tavolaro, S., Guarini, A., Foà, R. and Macino, G. (2009) Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of microRNA and mRNA expression profiles. Genes Chromosomes Cancer 48, 1069-1082.
40. Rainer, J., Ploner, C., Jesacher, S., Ploner, A., Eduardoff, M., Mansha, M., Wasim, M., Panzer-Grümayer, R., Trajanoski, Z., Niederegger, H. and Kofler, R. (2009) Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia 23, 746-752.
41. Decaux, O., Lodé, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jézéquel, P., Attal, M., Harousseau, J. L., Moreau, P., Bataille, R. et al. (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients. J. Clin. Oncol. 26, 4798-4805.
42. Anguiano, A., Tuchman, S. A., Acharya, C., Salter, K., Gasparetto, C., Zhan, F., Dhodapkar, M., Nevins, J., Barlogie, B., Shaughnessy, Jr, J. D. and Potti, A. (2009) Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J. Clin. Oncol. 27, 4197-4203.
43. Broyl, A., Hose, D., Lokhorst, H., de Knegt, Y., Peeters, J., Jauch, A., Bertsch, U., Buijs, A., Stevens-Kroef, M., Beverloo, H. B. et al. (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543-2553.
44. Pichiorri, F., Suh, S. S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P. et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 12885-12890.
45. Löffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüuller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K. et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat-3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333.
46. Roccaro, A. M., Sacco, A., Thompson, B., Leleu, X., Azab, A. K., Azab, F., Runnels, J., Jia, X., Ngo, H. T., Melhem, M. R. et al. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113, 6669-6680.
47. Lionetti, M., Biasiolo, M., Agnelli, L., Todoerti, K., Mosca, L., Fabris, S., Sales, G., Deliliers, G. L., Bicciato, S., Lombardi, L. et al. (2009) Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114, e20-e26.
48. Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D. R., Cartron, M. A., van Rhee, F., Nair, B., Waheed, S. et al. (2010) High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc. Natl. Acad. Sci. U.S.A. 107, 7904-7909.
49. Kim, C. and Paik, S. (2010) Gene-expression-based prognostic assays for breast cancer. Nat. Rev. Clin. Oncol. 7, 340-347.
50. Tabchy, A., Valero, V., Vidaurre, T., Lluch, A., Gomez, H., Martin, M., Qi, Y., Barajas-Figueroa, L. J., Souchon, E., Coutant, C. et al. (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16, 5351-5361.
51. Bertucci, F., Finetti, P., Birnbaum, D. and Viens, P. (2010) Gene expression profiling of inflammatory breast cancer. Cancer 116 Supp. 11, 2783-2793.
52. Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M. et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070.
53. Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T.,Ménard, S., Croce, C. M. and Tagliabue, E. (2009) MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69, 2195-2200.
54. Di Leva, G., Gasparini, P., Piovan, C., Ngankeu, A., Garofalo, M., Taccioli, C, Iorio, M. V., Li, M., Volinia, S., Alder, H. et al. (2010) MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer. J. Natl. Cancer Inst. 102, 706-721.
55. Sempere, L. F., Christensen, M., Silahtaroglu, A., Bak, M., Heath, C. V., Schwartz, G., Wells, W., Kauppinen, S. and Cole, C. N. (2007) Altered microRNA expression confined to specific epithelial cell subpopulation in breast cancer. Cancer Res. 67, 11612-11620.
56. Spizzo, R., Nicoloso, M. S., Lupini, L., Lu, Y., Fogarty, J., Rossi, S., Zagatti, B., Fabbri, M., Veronese, A., Liu, X. et al. (2010) miR-145 participates with TP53 in a deathpromoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ. 17, 246-254.
57. Almeida, M. I., Reis, R. M. and Calin, G. A. (2010) MYC-microRNA-9-metastasis connection in breast cancer. Cell Res. 20, 603-604.
58. Subramanian, J. and Simon, R. (2010) Gene expressionbased prognostic signatures in lung cancer: ready for clinical use? J. Natl. Cancer Inst. 102, 464-474.
59. Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H. et al. (2009) Diagnostic assay based on has-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27, 2030-2037.
60. Landi, M. T., Zhao, Y., Rotunno, M., Koshiol, J., Liu, H., Bergen, A. W., Rubagotti, M., Goldstein, A. M., Linnoila, I., Marincola, F. M. et al. (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16, 430-441.
61. Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T. et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198.
62. Incoronato, M., Garofalo, M., Urso, L., Romano, G., Quintavalle, C., Zanca, C., Iaboni, M., Nuovo, G., Croce, C. M. and Condorelli, G. (2010) miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 70, 3638-3646.
63. Liu, X., Sempere, L. F., Ouyang, H., Memoli, V. A., Andrew, A. S., Luo, Y., Demidenko, E., Korc, M., Shi, W., Preis, M. et al. (2010) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 120, 1298-1309.
64. Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa, I., Scagliotti, G. V., Papotti, M. and Allgayer, H. (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype. Mol. Cancer Res. 8, 1207-1216.
65. Busacca, S., Germano, S., de Cecco, L., Rinaldi, M., Comoglio, F., Favero, F., Murer, B., Mutti, L., Pierotti, M. and Gaudino, G. (2010) MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am. J. Respir. Cell Mol. Biol. 42, 312-319.
66. Gee, G. V., Koestler, D. C., Christensen, B. C., Sugarbaker, D. J., Ugolini, D., Ivaldi, G. P., Resnick, M. B., Houseman, E. A., Kelsey, K. T. and Marsit, C. J. (2010) Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int. J. Cancer 127, 2859-2869.
67. Satow, R., Shitashige, M., Kanai, Y., Takeshita, F., Ojima, H., Jigami, T., Honda, K., Kosuge, T., Ochiya, T., Hirohashi, S. and Yamada, T. (2010) Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin. Cancer Res. 16, 2518-2528.
68. Villanueva, A., Toffanin, S. and Llovet, J. M. (2008) Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol. 20, 444-453.
69. Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., Ambs, S., Chen, Y., Meltzer, P. S., Croce, C. M. et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437-1447.
70. Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S.W., Croce, C. M. and Dejean, A. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 107, 264-269.
71. Gramantieri, L., Fornari, F., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Bolondi, L. and Negrini, M. (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 15, 5073-5081.
72. Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L. and Gramantieri, L. (2010) MiR-199a-3p regulates mTOR and c-met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70, 5184-5193.
73. Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y. et al. (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology, doi:10.1053/j.gastro.2011.02.009.
74. Mutch, M. G. (2007) Molecular profiling and risk stratification of adenocarcinoma of the colon. J. Surg. Oncol. 96, 693-703.
75. Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., Yuen, S. T., Chan, T. L., Kwong, D. L., Au, G. K. et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, J. Am. Med. Assoc. 299, 425-436.
76. Sarver, A. L., French, A. J., Borralho, P. M., Thayanithy, V., Oberg, A. L., Silverstein, K. A., Morlan, B. W., Riska, S. M., Boardman, L. A., Cunningham, J. M. et al. (2009) Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9, 401.
77. Balaguer, F., Link, A., Lozano, J. J., Cuatrecasas, M., Nagasaka, T., Boland, C. R. and Goel, A. (2010) Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 70, 6609-6618.
78. Kulda, V., Pesta, M., Topolcan, O., Liska, V., Treska, V., Sutnar, A., Rupert, K., Ludvikova, M., Babuska, V., Holubec, Jr, L. and Cerny, R. (2010) Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Gen. Cytogen. 200, 154-160.
79. Ueda, T., Volinia, S., Okumura, H., Shimizu, M., Taccioli, C., Rossi, S., Alder, H., Liu, C. G., Oue, N., Yasui, W. et al. (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11, 136-146.
80. Gómez-Raposo, C., Mendiola, M., Barriuso, J., Hardisson, D. and Redondo, A. (2010) Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol. Oncol. 118, 88-92.
81. Dahiya, N. and Morin, J. P. (2010) MicroRNAs in ovarian carcinomas. Endocr. Relat. Cancer 17, F77-F89.
82. Bhattacharya, R., Nicoloso, M., Arvizo, R., Wang, E., Cortez, A., Rossi, S., Calin, G. A. and Mukherjee, P. (2009) MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 69, 9090-9095.
83. Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., Liu, C. G., Giannakakis, A., Alexiou, P., Hasegawa, K. et al. (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 7004-7009.
84. Gajewski, T. F., Louahed, J. and Brichard, V. G. (2010) Gene signature in melanoma associated with clinical activity. Cancer J. 16, 399-403.
85. Philippidou, D., Schmitt, M., Moser, D., Margue, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., Behrmann, I. and Kreis, S. (2010) Signatures of microRNAs and selected target genes in human melanoma. Cancer Res. 70, 4163-4173.
86. Caramuta, S., Egyházi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C. and Lui, W. O. (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 130, 2062-2070.
87. Braig, S., Mueller, D. W., Rothhammer, T. and Bosserhoff, A. K. (2010) MicroRNA miR196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol. Life Sci. 67, 3535-3548.
88. Vital, A. L., Tabernero, M. D., Castrillo, A., Rebelo, O., Tão, H., Gomes, F., Nieto, A. B., Resende Oliveira, C., Lopes, M. C. and Orfao, A. (2010) Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro-Oncol. 12, 991-1003.
89. Guan, Y., Mizoguchi, M., Yoshimoto, K., Hata, N., Shono, T., Suzuki, S. O., Araki, Y., Kuga, D., Nakamizo, A., Amano, T. et al. (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin. Cancer Res. 16, 4289-4297.
90. Kim, H., Huang, W., Jiang, X., Pennicooke, B., Park, P. J. and Johnson, M. D. (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc. Natl. Acad. Sci. U.S.A. 107, 2183-2188.
91. Cortez, M. A., Nicoloso, M. S., Shimizu, M., Rossi, S., Gopisetty, G., Molina, J. R., Carlotti, Jr, C., Tirapelli, D., Neder, L., Brassesco, M. S. et al. (2010) miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49, 981-990.
92. Papagiannakopoulos, T., Shapiro, A. and Kosik, K. S. (2008) MicroRNA-21 targets a network of key tumorsuppressive pathways in glioblastoma cells. Cancer Res. 68, 8164-8172.
93. Palmer, R. D., Murray, M. J., Saini, H. K., van Dongen, S., Abreu-Goodger, C., Muralidhar, B., Pett, M. R., Thornton, C. M., Nicholson, J. C., Enright, A. J. et al. (2010) Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 70, 2911-2923.
94. Hui, A. B. Y., Lenarduzzi, M., Krushei, T.,Waldron, L., Pintilie, M., Shi, W., Perez-Ordonez, B., Jurisica, I., O'Sullivan, B., Waldron, J. et al. (2010) Comprehensive microRNA profiling for head and neck squamous cell carcinoma. Clin. Cancer Res. 16, 1129-1139.
95. Giovanetti, E., Funel, N., Peters, G. J., Del Chiaro, M., Erozenci, L. A., Vasile, E., Leon, L. G., Pollina, L. E., Groen, A., Falcone, A. et al. (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528-4538.
96. Greither, T., Grochola, L. F., Udelnow, A., Lautenschläger, C., Würl, P. and Taubert, H. (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 126, 73-80.
97. Ambs, S., Prueitt, R. L., Yi, M., Hudson, R. S., Howe, T. M., Petrocca, F., Wallace, T. A., Liu, C. G., Volinia, S., Calin, G. A. et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162-6170.
98. Szczyrba, J., Löprich, E., Wach, S., Jung, V., Unteregger, G., Barth, S., Grobholz, R., Wieland, W., Stöhr, R., Hartmann, A.,Wullich, B. and Grässer, F. (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 8, 529-538.
99. Spahn, M., Kneitz, S., Scholz, C. J., Stenger, N., Rüdiger, T., Ströbel, P., Riedmiller, H. and Kneitz, B. (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127, 394-403.
100. Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., Wiggins, J. F. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211-215.
101. Pallante, P., Visone, R., Ferracin, M., Ferraro, A., Berlingieri, M. T., Troncone, G., Chiapetta, G., Liu, C. G., Santoro, M., Negrini, M. et al. (2006) MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497-508.
102. Visone, R., Pallante, P., Vecchione, A., Cirombella, R., Ferracin, M., Ferraro, A., Volinia, S., Coluzzi, S., Leone, V., Borbone, E. et al. (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26, 7590-7595.
103. Varadhachary, G. R., Talantov, D., Raber, M. N., Meng, C., Hess, K. R., Jatkoe, T., Lenzi, R., Spigel, D. R., Wang, Y., Greco, F. A. et al. (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J. Clin. Oncol. 26, 4442-4448.
104. Rosenfeld, N., Aharonov, R., Meiri, E., Rosenwald, S., Spector, Y., Zepeniuk, M., Benjamin, H., Shabes, N., Tabak, S., Levy, A. et al. (2008) MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26, 462-469.
105. Rosenwald, S., Gilad, S., Benjamin, S., Lebanony, D., Dromi, N., Faerman, A., Benjamin, H., Tamir, R., Ezagouri, M., Goren, E. et al. (2010) Validation of a microRNA-based qRT-PCR test for accurate identification of tumor origin. Mod. Pathol. 23, 814-823.
106. Ma, J., Dong, C. and Ji, C. (2010) MicroRNA and drug resistance. Cancer Gene Ther. 17, 523-531.
107. Nicoloso, M. S., Sun, H., Spizzo, R., Kim, H., Wickramasinghe, P., Shimizu, M.,Wojcik, S. E., Ferdin, J., Kunej, T., Xiao, L. et al. (2010) Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 70, 2789-2798.
108. Christensen, B. C., Avissar-Whiting, M., Ouellet, L. G., Butler, R. A., Nelson, H. H., McClean, M. D., Marsit, C. J. and Kelsey, K. T. (2010) Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin. Cancer Res. 16, 3713-3720.
109. Jazszewski, K., Liyanarachchi, S., Swierniak, M., Pachucki, J., Ringel, M. D., Jarzab, B. and de la Chapelle, A. (2009) Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 1502-1505.
110. Bao, B.-Y., Pao, J.-B., Huang, C.-N., Pu, Y.-S., Chang, T.-Y., Lan, Y.-H., Lu, T.-L., Lee, H.-Z., Juang, S.-H., Chen, L.-M., Hsieh, C.-J. and Huang, S. H. (2011) Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin. Cancer Res. 17, 928-936.
111. Liang, D., Meyer, L., Chang, D.W., Lin, J., Pu, X., Ye, Y., Gu, J., Wu, X. and Lu, K. (2010) Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 70, 9765-9776.
112. Godshalk, S. E., Paranjabe, T., Nallur, S., Speed, W., Chan, E., Molinaro, A. M., Bacchiocchi, A., Hoyt, K., Tworkoski, K., Stern, D. F. et al. (2011) A variant in a microRNA complementary site in the 3′UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 30, 1542-1550.
113. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513-10518.
114. Ng, E. K. O., Chong, W.W. S., Jin, H., Lam, E. K., Shin, V. Y., Yu, J., Poon, T. C., Ng, S. S. and Sung, J. J. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-1381.
115. Li, A., Omura, N., Hong, S. M., Vincent, A., Walter, K., Griffith, M., Borges, M. and Goggins, M. (2010) Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 70, 5226-5237.
116. Silva, J., Garcìa, V., Zaballos, Â ., Provencio, M., Lombardía, L., Almonacid, L., García, J. M., Domínguez, G., Peña, C., Diaz, R. et al. (2010) Vesicle-related microRNAs in plasma of NSCLC patients and correlation with survival. Eur. Respir. J. 37, 617-623.
117. Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., Kosuga, T., Konishi, H., Morimura, R., Deguchi, K., Fujiwara, H. et al. (2010) Circulating microRNAs in plasma from patients with gastric cancers. Br. J. Cancer 102, 1174-1179.
118. Li, Y., Guessous, F., Zhang, Y., Dipierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D. et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69, 7569-7576.
119. Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S. and Ørum, H. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201.
120. Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D. and Bader, A. G. (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70, 5923-5930.
121. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R. et al. (2009) Therapeutic delivery of miR-26a inhibits cancer cell proliferation and induces tumor-specific apoptosis. Cell 137, 1005-1017.
122. Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L. and Weinberg, R. A. (2009) A pleiotropically acting microRNA, miR31, inhibits breast cancer metastasis. Cell 137, 1032-1046.
123. Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R. U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A. G., Brown, D. and Ochiya, T. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181-187.
124. Taulli, R., Bersani, F., Foglizzo, V., Linari, A., Vigna, E., Ladanyi, M., Tuschl, T. and Ponzetto, C. (2009) The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J. Clin. Invest. 119, 2366-2378.